Publications by authors named "Xiuhua Sun"

Mantle cell lymphoma (MCL) exhibits significant biological and clinical heterogeneity, necessitating a refined prognostic model. According to the drawbacks of existing models which do not truly define the complexity of the disease, we used the clinical and molecular data from nine medical centers of China to validate the predictive utility of progression of disease within 24 months (POD24), and also established a novel prognostic risk model to predict the survival outcome of MCL patients. POD24 occurred in 37.

View Article and Find Full Text PDF

Background: Disease progression within 24 months (POD24) significantly impacts overall survival (OS) in patients with follicular lymphoma (FL). This study aimed to develop a robust predictive model, FLIPI-C, using a machine learning approach to identify FL patients at high risk of POD24.

Methods: A cohort of 1,938 FL patients (FL1-3a) from seventeen centers nationwide in China was randomly divided into training and internal validation sets (2:1 ratio).

View Article and Find Full Text PDF

Follicular lymphoma (FL) is an immune-responsive tumor with spontaneous remission. T cells play a pivotal role in the anti-lymphoma immune response. However, the dynamics of T cells during treatment, their impact on FL clinical outcomes, and the risk factors contributing to T-cell cytopenia remain largely unexplored.

View Article and Find Full Text PDF
Article Synopsis
  • A phase 3 trial compared the effectiveness and safety of zuberitamab combined with CHOP chemotherapy (Hi-CHOP) against rituximab combined with CHOP (R-CHOP) in patients with untreated CD20-positive diffuse large B-cell lymphoma (DLBCL).
  • The trial involved 487 patients, with a primary focus on the objective response rate (ORR) after six treatment cycles, finding that Hi-CHOP achieved a similar ORR to R-CHOP while demonstrating a significantly higher complete response (CR) rate in some analyses.
  • Long-term follow-up indicated that Hi-CHOP patients experienced improved duration of response (DOR), progression-free survival (PFS), and overall survival
View Article and Find Full Text PDF

The capsaicin analogue -(4-hydroxy-3-methoxybenzyl) acrylamide (HMBA) was linked with polylauryl methacrylate--poly(2-(,-dimethylamino)ethyl methacrylate) (PLMA--PDMAEMA) via a quaternization reaction with 4-(acrylamidomethyl)-2-methoxyphenyl 2-chloroacetate (AAMPCA). The amphiphilic copolymers were capable of transforming its structure in response to the solvent change from aprotic to protic, which was verified by the H NMR spectrum. The resulting cationic copolymers underwent a hydrolysis process in water, yielding zwitterionic groups on surfaces.

View Article and Find Full Text PDF
Article Synopsis
  • Some follicular lymphoma (FL) patients on a "watch and wait" strategy experience quick disease progression, prompting researchers to find ways to identify these individuals and develop a risk score for better screening at diagnosis.
  • In a study involving 411 FL patients from 16 cancer centers, 35% required treatment within 24 months, with a significantly lower 5-year progression-free survival rate (62.3% vs. 89.5%) for those needing treatment early.
  • Five key factors were identified as predictors for needing treatment within 24 months: advanced disease stages, high β microglobulin levels, low lymphocyte-to-monocyte ratios, bone marrow involvement, and spleen enlargement; these factors can help pinpoint patients who
View Article and Find Full Text PDF

Objective: The objective of this research is to examine the therapy and outlook of pediatric primary central nervous system Burkitt lymphomas.

Methods: This study involves a retrospective analysis of the clinical data of a child with primary central nervous system Burkitt lymphoma who underwent treatment in our department. In addition, pertinent literature was reviewed to provide a comprehensive understanding of the topic.

View Article and Find Full Text PDF
Article Synopsis
  • - Patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) typically have a poor prognosis, but Loncastuximab tesirine (Lonca), an antibody drug, has shown significant effectiveness in a global study (LOTIS-2).
  • - The China bridging pivotal phase 2 study treated eligible patients who had already undergone at least two previous treatments, showing an overall response rate of 51.6% and a complete response rate of 23.4% after a median of 4 cycles of treatment.
  • - While Lonca was generally well-tolerated, there were notable side effects, particularly in blood-related events, with serious treatment-emergent adverse events reported in 35 out
View Article and Find Full Text PDF

Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease with varying characteristics, in terms of genomic variation, cell morphology and clinical presentation. At present, only ~66% of patients are cured with initial treatment and those with refractory DLBCL exhibit a poor prognosis. Thus, further investigations into novel effective treatment options for DLBCL are required.

View Article and Find Full Text PDF

Mantle cell lymphoma (MCL) is an uncommon and incurable B-cell lymphoma subtype that has an aggressive course. Hepatitis B virus (HBV) infection has been associated with an increased risk for B-cell lymphomas, and is characterized by distinct clinical and genetic features. Here, we showed that 9.

View Article and Find Full Text PDF

HLX01 (HanliKang) is a rituximab biosimilar that showed bioequivalence to reference rituximab in untreated CD20-positive diffuse large B-cell lymphoma (DLBCL) in the phase 3 HLX01-NHL03 study. Here, we report the 5-year follow-up results from the open-label extension part. Patients were randomised to either rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) or HLX01 plus CHOP (H-CHOP) every 21 days for up to six cycles.

View Article and Find Full Text PDF

Purpose: Patients with peripheral T-cell lymphomas (PTCL) in the relapsed or refractory (r/r) setting have only a limited number of therapies available, and the prognosis is extremely poor. SHR2554 is an oral inhibitor against EZH2, a rational therapeutic target for lymphomas.

Patients And Methods: This was a multicenter, two-part, phase I study of SHR2554 in r/r mature lymphoid neoplasms.

View Article and Find Full Text PDF

Background: Exosomes play important roles in intercellular communication by delivering microRNAs (miRNAs) that mediate tumor initiation and development, including those in diffuse large B cell lymphoma (DLBCL). To date, however, limited studies on the inhibitory effect of exosomes derived from human bone marrow mesenchymal stem cells (hBMSCs) on DLBCL progression have been reported. Therefore, this study aimed to investigate the role of hBMSC exosomes carrying microRNA-124-3p in the development of DLBCL.

View Article and Find Full Text PDF

Regimens based on Bruton's tyrosine kinase inhibitors (BTKi) have been increasingly used to treat mantle cell lymphoma (MCL). A real-world multicenter study was conducted to characterize treatment patterns and outcomes in patients with newly diagnosed MCL by Chinese Hematologist and Oncologist Innovation Cooperation of the Excellent (CHOICE). The final analysis included 1261 patients.

View Article and Find Full Text PDF
Article Synopsis
  • Mantle cell lymphoma (MCL) is a rare subtype of non-Hodgkin lymphoma with varying treatment approaches across regions, particularly in Asia and China, where specific data on treatment outcomes for Asian patients is limited.
  • This study analyzed 805 MCL patients in China from 1999 to 2019, using statistical methods to evaluate survival rates and factors influencing prognosis.
  • Findings indicate that treatments like high-dose cytarabine and autologous stem cell transplantation improve survival rates, emphasizing the importance of maintenance therapy and the potential benefits of newer drugs for relapsed/refractory MCL patients.
View Article and Find Full Text PDF

Lymphoma is a hematologic malignancy which mainly consists of Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL). Although systemic chemotherapy, radiotherapy, and other advanced therapeutics, including rituximab or immune checkpoint inhibitors, have improved the prognosis in recent decades, there are still a number of patients with relapsed or refractory (R/R) lymphoma with a poor prognosis. Chimeric antigen receptor (CAR) T-cell therapy has provided a curative option for patients with relapsed or refractory lymphoma.

View Article and Find Full Text PDF

Hodgkin's lymphoma (HL) is a unique B‑cell lymphoproliferative malignancy that has a critical pathogenesis characterized by a sparse population of Hodgkin and Reed‑Sternberg cells surrounded by numerous dysfunctional immune cells. Although systemic chemotherapy with or without radiotherapy, has significantly improved the prognosis of the majority of patients with HL, a subset of patients remains refractory to first‑line therapy or relapse after achieving an initial response. With the increased understanding of the biology and microenvironment of HL, novel strategies with notable efficacy and manageable toxicity, including targeted therapies, immunotherapy and cell therapy have emerged.

View Article and Find Full Text PDF

Background: KL-A167 is a fully humanized monoclonal antibody targeting programmed cell death-ligand 1. This phase 2 study aimed to evaluate the efficacy and safety of KL-A167 in Chinese patients with previously treated recurrent or metastatic (R/M) nasopharyngeal carcinoma (NPC).

Methods: This was a multicentre, single-arm, phase 2 study of KL-A167 in R/M NPC (KL167-2-05-CTP) (NCT03848286), conducted at 42 hospitals across the People's Republic of China.

View Article and Find Full Text PDF

Background: The difference between clinical characteristics and outcomes between follicular lymphoma grade 1-2 (FL1-2) and FL3a defined pathologically remains unclear, resulting in uncertainty how to treat FL3a. However, it may be crucial for clinicians to discriminate grade 3a and grade 1-2 for predicting prognosis and thus making treatment decisions.

Methods: We compared 1403 patients with FL1-2 and 765 patients with FL3a diagnosed between January 2000 and December 2020 from fifteen centers nationwide in China to describe differences in clinical characteristics and outcomes.

View Article and Find Full Text PDF

Purpose: To investigate the efficacy and safety of the novel orally active PI3Kδ inhibitor in relapsed and/or refractory patients with follicular lymphoma (FL) who had received at least two prior systemic treatments.

Patients And Methods: Histologically confirmed relapsed and/or refractory patients with FL with disease progression after receiving second-line or greater systemic therapy were enrolled. Linperlisib was administered at 80 mg every day, orally in a 28-day cycle until disease progression or intolerable toxicity occurred.

View Article and Find Full Text PDF

Hemophagocytic lymphohistiocytosis (HLH) is a severe syndrome of pathological immune activation caused by activated macrophages and cytotoxic T cells. We report a 65-year-old male Chinese patient with typical HLH features caused by peripheral T-cell lymphoma and then received chemotherapy. However, though the patient's symptoms and signs improved much, his liver function, especially bilirubin, worsened which could be caused by overwhelming cytokines production.

View Article and Find Full Text PDF

Salvia miltiorrhiza Bunge (SMB) has unambiguous biological functions in cardiovascular diseases, thus has been processed into different medicine forms. However, universal analytical method for fast quantification of bioactive compounds in SMB and SMB derived products is still missing. In this study, a polarity switching strategy was developed and optimized, which enabled the detection of the target compound in both positive and negative ion modes in a single run.

View Article and Find Full Text PDF

Background: Nearly all anti-PD-1 antibodies are of the IgG4 isotype, and thus possess residual FcR effector functions. Such anti-PD-1 antibodies are also associated with immune tolerance and escape due to instability of the CH3 domain and Fc-Fc interaction. In this trial, we examined the efficacy and safety of penpulimab, a novel IgG1 anti-PD-1 antibody that does not bind to the Fc receptor, in patients with refractory or relapsed classical Hodgkin lymphoma (R/R cHL).

View Article and Find Full Text PDF

Purpose: Hemophagocytic lymphohistiocytosis (HLH), especially lymphoma-associated HLH (LA-HLH), is a refractory immune disorder with high mortality. There is still no consensus regarding the ideal treatment for LA-HLH.

Methods: We performed a prospective multicenter study (NCT04077905) to explore the efficacy of a modified DEP regimen as induction therapy for LA-HLH.

View Article and Find Full Text PDF

Background: Ibrutinib has revolutionized the treatment of mantle cell lymphoma (MCL). Both ibrutinib monotherapy and ibrutinib-based combination therapy are important salvage options for patients with relapsed/refractory (R/R) MCL. The real-world efficacy and safety profile of the two strategies in Chinese patients with R/R MCL remain unclarified.

View Article and Find Full Text PDF

A PHP Error was encountered

Severity: Warning

Message: fopen(/var/lib/php/sessions/ci_sessionbpo7t91n2opkrrmo3100qrj75ugi6na1): Failed to open stream: No space left on device

Filename: drivers/Session_files_driver.php

Line Number: 177

Backtrace:

File: /var/www/html/index.php
Line: 316
Function: require_once

A PHP Error was encountered

Severity: Warning

Message: session_start(): Failed to read session data: user (path: /var/lib/php/sessions)

Filename: Session/Session.php

Line Number: 137

Backtrace:

File: /var/www/html/index.php
Line: 316
Function: require_once